Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of coronavirus disease 2019 (COVID-19) and continues to be a major health concern worldwide. Strategies to protect individuals at high risk of COVID-19 are critical but are currently a largely unmet need. We evaluated the oral antiviral drug ensitrelvir, which specifically targets the SARS-CoV-2 3CL protease, for its efficacy as a pre-exposure prophylactic treatment. Aged BALB/c mice were subcutaneously treated with various doses of ensitrelvir 24 h prior to a lethal SARS-CoV-2 challenge infection. Mouse body weight changes, survival rates, and viral titers in the lungs were evaluated, and plasma concentrations of ensitrelvir were determined. A single subcutaneous administration of ensitrelvir at 64 mg/kg or greater 24 h prior to SARS-CoV-2 challenge infection significantly protected aged mice against lethality and inhibited body weight loss. Pharmacokinetic analysis of ensitrelvir in the aged mice suggested that plasma concentrations ≥2.99 μg/mL resulted in a significant prophylactic effect against SARS-CoV-2 infection. In the aged mouse prophylaxis model, SARS-CoV-2 titers were suppressed in the lungs of mice treated with ensitrelvir 24 h prior to challenge infection, suggesting that the prophylactic administration of ensitrelvir exerted its prophylactic effect by suppressing viral proliferation. These findings suggest that ensitrelvir is a candidate drug for pre-exposure prophylactic treatment of individuals at high risk of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:224 |
|---|---|
| Enthalten in: |
Antiviral research - 224(2024) vom: 10. März, Seite 105852 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nobori, Haruaki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.antiviral.2024.105852 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369186303 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369186303 | ||
| 003 | DE-627 | ||
| 005 | 20240318234546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240302s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.antiviral.2024.105852 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM369186303 | ||
| 035 | |a (NLM)38428748 | ||
| 035 | |a (PII)S0166-3542(24)00060-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nobori, Haruaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of coronavirus disease 2019 (COVID-19) and continues to be a major health concern worldwide. Strategies to protect individuals at high risk of COVID-19 are critical but are currently a largely unmet need. We evaluated the oral antiviral drug ensitrelvir, which specifically targets the SARS-CoV-2 3CL protease, for its efficacy as a pre-exposure prophylactic treatment. Aged BALB/c mice were subcutaneously treated with various doses of ensitrelvir 24 h prior to a lethal SARS-CoV-2 challenge infection. Mouse body weight changes, survival rates, and viral titers in the lungs were evaluated, and plasma concentrations of ensitrelvir were determined. A single subcutaneous administration of ensitrelvir at 64 mg/kg or greater 24 h prior to SARS-CoV-2 challenge infection significantly protected aged mice against lethality and inhibited body weight loss. Pharmacokinetic analysis of ensitrelvir in the aged mice suggested that plasma concentrations ≥2.99 μg/mL resulted in a significant prophylactic effect against SARS-CoV-2 infection. In the aged mouse prophylaxis model, SARS-CoV-2 titers were suppressed in the lungs of mice treated with ensitrelvir 24 h prior to challenge infection, suggesting that the prophylactic administration of ensitrelvir exerted its prophylactic effect by suppressing viral proliferation. These findings suggest that ensitrelvir is a candidate drug for pre-exposure prophylactic treatment of individuals at high risk of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Ensitrelvir | |
| 650 | 4 | |a Pre-exposure prophylactic treatment | |
| 650 | 4 | |a Protease inhibitor | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a ensitrelvir |2 NLM | |
| 650 | 7 | |a PX665RAA3H |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Indazoles |2 NLM | |
| 650 | 7 | |a Triazines |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 700 | 1 | |a Baba, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroda, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Kaoru |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Kazumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Shinpei |e verfasserin |4 aut | |
| 700 | 1 | |a Watari, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Tachibana, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Teruhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Fukao, Keita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 224(2024) vom: 10. März, Seite 105852 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
| 773 | 1 | 8 | |g volume:224 |g year:2024 |g day:10 |g month:03 |g pages:105852 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.antiviral.2024.105852 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 224 |j 2024 |b 10 |c 03 |h 105852 | ||